Aeon Biopharma Inc (AEON)

$0.23 0.00 (-1.70%)
Market Cap 11.72M
Revenue (ttm) 0.00
Net Income (ttm) -39.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 473,800
Avg Vol 3,289,892
Day's Range N/A - N/A
Shares Out 49.88M
Stochastic %K 1%
Beta 0.65
Analysts Strong Sell
Price Target $1.65

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutic...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 354 6499
Address:
5 Park Plaza, Suite 1750, Irvine, United States
RetiredMilitary
RetiredMilitary Sep. 10 at 3:48 PM
$AEON
0 · Reply
memo_18
memo_18 Sep. 10 at 3:42 PM
$AEON
0 · Reply
Johnnyshots
Johnnyshots Sep. 10 at 3:41 PM
$AEON 150 in volume. Just send the damn thing !
0 · Reply
RetiredMilitary
RetiredMilitary Sep. 10 at 3:30 PM
$AEON Powerful criminals aren't they?
0 · Reply
XkaliburTrading
XkaliburTrading Sep. 10 at 3:26 PM
It's a great morning to be alive, everybody! I hope you're all having an amazing start to your day. The XKALIBUR TRADING Team is locked in, sharing ideas, staying engaged, and helping each other spot opportunities like $TNON , $DBGI , $IPDN and $AEON then B🎯🎯M smashing levels and still spotting potential bangers along the way! That's the power of teamwork—more eyes, more ideas, and everyone working together. I hope you all have an amazing day. Let's keep it rolling. LFG, XKALIBUR TRADING Team! 🔥📈
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:23 PM
$AEON 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data. *****
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:22 PM
$AEON Aeon Biopharma is positioning itself as a groundbreaking innovator in the multi-billion-dollar neuroscience market and is poised for a pivotal breakthrough with its best-in-class BOTOX® biosimilar, ABP-450. Thanks to a masterfully executed balance sheet restructuring—which slashed debt by over 90%—and a fully funded cash runway extending well into 2027, this medical gem possesses the fundamental strength to disrupt the market from the bottom up and offer visionary investors monumental upside potential.
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:20 PM
$AEON 🔥 What’s the upside?: The FDA has fundamentally endorsed the company’s analytical strategy during a "Type 2a" meeting. This significantly reduces regulatory development risk.
0 · Reply
Tradingistheway
Tradingistheway Sep. 10 at 3:17 PM
$AEON $1
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:15 PM
$AEON Conference appearance: Management is presenting live today, Thursday, September 10, at the Lake Street BIG10 Conference in New York. September 9, 2026 (Last night): HIGHLIGHT: Announcement of highly successful pilot stability data (forced degradation) confirming a molecular structure identical to BOTOX®. Backed by this sensational laboratory data, AEON Biopharma is demonstrating to the entire medical community that its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX®! Driven by a top-tier leadership team of former FDA executives and rock-solid financing, this biotech gem is catapulting itself today from a state of extreme undervaluation straight to the top of global watchlists. 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.
0 · Reply
Latest News on AEON
Aeon Biopharma announces results from ABP-450 pilot forced degradation study

2026-09-09T12:10:18.000Z - 1 day ago

Aeon Biopharma announces results from ABP-450 pilot forced degradation study

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

Sep 9, 2026, 8:00 AM EDT - 1 day ago

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

Aeon Biopharma initiated with a Buy at Laidlaw

2026-09-09T10:00:10.000Z - 1 day ago

Aeon Biopharma initiated with a Buy at Laidlaw

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference

Aug 31, 2026, 8:00 AM EDT - 10 days ago

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference

Aeon Biopharma designates Paul Lee as acting chief regulatory officer

2026-08-24T12:10:37.000Z - 17 days ago

Aeon Biopharma designates Paul Lee as acting chief regulatory officer

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

Aug 24, 2026, 8:00 AM EDT - 17 days ago

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

Aug 19, 2026, 8:00 AM EDT - 22 days ago

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright

2026-08-16T12:58:06.000Z - 25 days ago

Aeon Biopharma price target lowered to $1.20 from $5 at H.C. Wainwright

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 12, 2026, 4:15 PM EDT - 4 weeks ago

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Earnings release: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 4 weeks ago

AEON Biopharma Earnings release: Q2 2026

AEON Biopharma Quarterly report: Q2 2026

Aug 12, 2026, 4:00 PM EDT - 4 weeks ago

AEON Biopharma Quarterly report: Q2 2026

AEON Biopharma Slides: Corporate presentation

Aug 11, 2026, 7:00 AM EDT - 4 weeks ago

AEON Biopharma Slides: Corporate presentation

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

Aug 3, 2026, 4:15 PM EDT - 5 weeks ago

AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards

Lake Street starts Aeon Biopharma at Buy on potential of Botox competitor

2026-07-30T13:01:41.000Z - 6 weeks ago

Lake Street starts Aeon Biopharma at Buy on potential of Botox competitor

Aeon Biopharma initiated with a Buy at Lake Street

2026-07-30T11:55:49.000Z - 6 weeks ago

Aeon Biopharma initiated with a Buy at Lake Street

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

Jul 27, 2026, 7:52 AM EDT - 6 weeks ago

Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards

Aeon announces pricing of upsized $13.75M public offering

2026-07-14T14:15:16.000Z - 1 month ago

Aeon announces pricing of upsized $13.75M public offering

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

Jul 14, 2026, 8:00 AM EDT - 1 month ago

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

AEON Biopharma Registration statement: Registration filing

Jul 9, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Registration statement: Registration filing

AEON Biopharma Registration statement: Registration filing

Jul 8, 2026, 8:00 AM EDT - 2 months ago

AEON Biopharma Registration statement: Registration filing

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

Jun 4, 2026, 7:00 AM EDT - 3 months ago

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 4:05 PM EDT - 3 months ago

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Earnings release: Q1 2026

AEON Biopharma Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

AEON Biopharma Quarterly report: Q1 2026

Aeon Biopharma management to meet virtually with Lake Street

2026-05-14T14:19:48.000Z - 3 months ago

Aeon Biopharma management to meet virtually with Lake Street

AEON Biopharma Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 3 months ago

AEON Biopharma Slides: Corporate presentation

AEON Biopharma Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AEON Biopharma Proxy statement: Proxy filing

AEON Biopharma Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AEON Biopharma Proxy statement: Proxy filing

AEON Biopharma Sets Annual Shareholder Meeting

Apr 24, 2026, 4:05 PM EDT - 4 months ago

AEON Biopharma Sets Annual Shareholder Meeting

Aeon receives additional notice related to NYSE American listing standards

2026-04-06T01:20:06.000Z - 5 months ago

Aeon receives additional notice related to NYSE American listing standards

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Apr 3, 2026, 4:10 PM EDT - 5 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

Apr 3, 2026, 4:05 PM EDT - 5 months ago

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Mar 30, 2026, 4:05 PM EDT - 5 months ago

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

AEON Biopharma Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

AEON Biopharma Annual report: Q4 2025

AEON Biopharma Earnings release: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

AEON Biopharma Earnings release: Q4 2025

Aeon Biopharma announces FDA feedback after Type 2a meeting

2026-03-25T12:17:47.000Z - 5 months ago

Aeon Biopharma announces FDA feedback after Type 2a meeting

Aeon Biopharma appoints John Bencich as CFO

2026-03-09T20:45:55.000Z - 6 months ago

Aeon Biopharma appoints John Bencich as CFO

ACHV

Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders

2026-02-09T21:45:15.000Z - 7 months ago

Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders

AEON Biopharma Registration statement: Registration Filing

Feb 9, 2026, 7:00 AM EST - 7 months ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Slides: Corporate presentation

Jan 22, 2026, 7:00 AM EST - 7 months ago

AEON Biopharma Slides: Corporate presentation

Aeon Biopharma reports BPD Type 2a meeting with FDA

2026-01-21T21:25:21.000Z - 7 months ago

Aeon Biopharma reports BPD Type 2a meeting with FDA

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Jan 21, 2026, 4:05 PM EST - 7 months ago

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

AEON Biopharma Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 8 months ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Dec 15, 2025, 4:05 PM EST - 8 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA

2025-11-20T13:46:22.000Z - 9 months ago

Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Nov 20, 2025, 8:30 AM EST - 9 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Aeon Biopharma reports Q3 EPS (39c) vs ($11.24) last year

2025-11-14T13:35:33.000Z - 10 months ago

Aeon Biopharma reports Q3 EPS (39c) vs ($11.24) last year

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 14, 2025, 8:30 AM EST - 10 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

AEON Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

AEON Biopharma Quarterly report: Q3 2025

AEON Biopharma Earnings release: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

AEON Biopharma Earnings release: Q3 2025

AEON Biopharma Proxy statement: Proxy Filing

Nov 14, 2025, 7:00 AM EST - 10 months ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Nov 13, 2025, 8:30 AM EST - 10 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

AEON Biopharma Proxy statement: Proxy Filing

Nov 13, 2025, 7:00 AM EST - 10 months ago

AEON Biopharma Proxy statement: Proxy Filing

Aeon Biopharma announces FDA BPD Type 2a meeting for ABP-450

2025-10-01T12:20:41.000Z - 11 months ago

Aeon Biopharma announces FDA BPD Type 2a meeting for ABP-450

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Oct 1, 2025, 8:00 AM EDT - 11 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Quarterly report: Q2 2025

AEON Biopharma Earnings release: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Earnings release: Q2 2025

AEON Biopharma Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 19, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

AEON Biopharma Earnings release: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Earnings release: Q1 2025

AEON Biopharma Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

AEON Biopharma Quarterly report: Q1 2025

AEON Biopharma Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 25, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Aeon Biopharma appoints Rob Bancroft as CEO

2025-04-21T20:16:30.000Z - 1 year ago

Aeon Biopharma appoints Rob Bancroft as CEO

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Apr 21, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

AEON Biopharma Announces CEO Transition

Mar 27, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces CEO Transition

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

AEON Biopharma Annual report: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Annual report: Q4 2024

AEON Biopharma Earnings release: Q4 2024

Mar 24, 2025, 9:00 AM EDT - 1 year ago

AEON Biopharma Earnings release: Q4 2024

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

AEON Biopharma Proxy statement: Proxy Filing

Jan 23, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Proxy statement: Proxy Filing

Jan 13, 2025, 7:00 AM EST - 1 year ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Quarterly report: Q3 2024

AEON Biopharma Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

AEON Biopharma Earnings release: Q3 2024

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Registration statement: Registration Filing

Aug 15, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AEON Biopharma Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q2 2024

AEON Biopharma Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q2 2024

AEON Biopharma Registration statement: Registration Filing

Jul 23, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Registration statement: Registration Filing

May 31, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

May 14, 2024, 4:05 PM EDT - 2 years ago

AEON Biopharma Reports First Quarter 2024 Financial Results

AEON Biopharma Proxy statement: Proxy Filing

May 14, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Quarterly report: Q1 2024

AEON Biopharma Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q1 2024

AEON Biopharma Provides Update on Development Pipeline

May 9, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

May 3, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

AEON Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Proxy statement: Proxy Filing

AEON Biopharma Registration statement: Registration Filing

Apr 2, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

AEON Biopharma Annual report: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Annual report: Q4 2023

AEON Biopharma Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Earnings release: Q4 2023

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

AEON Biopharma Registration statement: Registration Filing

Nov 24, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Reports Third Quarter 2023 Financial Results

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

AEON Biopharma Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Quarterly report: Q3 2023

AEON Biopharma Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

AEON Biopharma Earnings release: Q3 2023

AEON Biopharma Registration statement: Registration Filing

Oct 23, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Registration statement: Registration Filing

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 29, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 24, 2023, 8:00 AM EDT - 3 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

RetiredMilitary
RetiredMilitary Sep. 10 at 3:48 PM
$AEON
0 · Reply
memo_18
memo_18 Sep. 10 at 3:42 PM
$AEON
0 · Reply
Johnnyshots
Johnnyshots Sep. 10 at 3:41 PM
$AEON 150 in volume. Just send the damn thing !
0 · Reply
RetiredMilitary
RetiredMilitary Sep. 10 at 3:30 PM
$AEON Powerful criminals aren't they?
0 · Reply
XkaliburTrading
XkaliburTrading Sep. 10 at 3:26 PM
It's a great morning to be alive, everybody! I hope you're all having an amazing start to your day. The XKALIBUR TRADING Team is locked in, sharing ideas, staying engaged, and helping each other spot opportunities like $TNON , $DBGI , $IPDN and $AEON then B🎯🎯M smashing levels and still spotting potential bangers along the way! That's the power of teamwork—more eyes, more ideas, and everyone working together. I hope you all have an amazing day. Let's keep it rolling. LFG, XKALIBUR TRADING Team! 🔥📈
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:23 PM
$AEON 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data. *****
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:22 PM
$AEON Aeon Biopharma is positioning itself as a groundbreaking innovator in the multi-billion-dollar neuroscience market and is poised for a pivotal breakthrough with its best-in-class BOTOX® biosimilar, ABP-450. Thanks to a masterfully executed balance sheet restructuring—which slashed debt by over 90%—and a fully funded cash runway extending well into 2027, this medical gem possesses the fundamental strength to disrupt the market from the bottom up and offer visionary investors monumental upside potential.
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:20 PM
$AEON 🔥 What’s the upside?: The FDA has fundamentally endorsed the company’s analytical strategy during a "Type 2a" meeting. This significantly reduces regulatory development risk.
0 · Reply
Tradingistheway
Tradingistheway Sep. 10 at 3:17 PM
$AEON $1
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:15 PM
$AEON Conference appearance: Management is presenting live today, Thursday, September 10, at the Lake Street BIG10 Conference in New York. September 9, 2026 (Last night): HIGHLIGHT: Announcement of highly successful pilot stability data (forced degradation) confirming a molecular structure identical to BOTOX®. Backed by this sensational laboratory data, AEON Biopharma is demonstrating to the entire medical community that its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX®! Driven by a top-tier leadership team of former FDA executives and rock-solid financing, this biotech gem is catapulting itself today from a state of extreme undervaluation straight to the top of global watchlists. 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.
0 · Reply
johnrivers0110
johnrivers0110 Sep. 10 at 3:15 PM
$AHMA 😈 oh those top movers won't last long... & Why buy a top when you can buy a bottom anyways ... All gains to AHMA🐇🚀🚀🚀 The FiB 🔺 $AEON 🩸 $DBGI 🩸 $TNON 🩸 $BTC.X
1 · Reply
Zohan_69
Zohan_69 Sep. 10 at 3:13 PM
$AEON $AEON September 9, 2026 (Last night): HIGHLIGHT: Announcement of highly successful pilot stability data (forced degradation) confirming a molecular structure identical to BOTOX®. 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data. The exact catalyst: Fresh, top-tier news! Last night, AEON released highly positive results from a pilot degradation study that scientifically substantiates the molecular and analytical equivalence of its biosimilar, ABP-450, to BOTOX®. A scientific breakthrough: The study demonstrates stability and oxidation patterns comparable to the original BOTOX®.
0 · Reply
FonsieTrader
FonsieTrader Sep. 10 at 3:07 PM
$AEON coulkd make a big JUMP over $0.34!! stay closely
0 · Reply
RetiredMilitary
RetiredMilitary Sep. 10 at 3:05 PM
$AEON
0 · Reply
topstockalerts
topstockalerts Sep. 10 at 2:54 PM
Top Gainers PT2 $AEON $VIOT $ATER $INDP $TPET
0 · Reply
888energy
888energy Sep. 10 at 2:53 PM
$AEON i hate how this never holds
0 · Reply
Dipps
Dipps Sep. 10 at 2:45 PM
$AEON https://www.tipranks.com/news/the-fly/aeon-biopharma-initiated-with-a-buy-at-laidlaw-thefly-news
0 · Reply
STACKD0E
STACKD0E Sep. 10 at 2:45 PM
$AEON 👁
0 · Reply
RetiredMilitary
RetiredMilitary Sep. 10 at 2:40 PM
$AEON
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 2:39 PM
$AEON 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.
0 · Reply
Johnnyshots
Johnnyshots Sep. 10 at 2:38 PM
$AEON Starting to curl 📈
0 · Reply
Zohan_69
Zohan_69 Sep. 10 at 2:38 PM
$AEON Conference appearance: Management is presenting live today, Thursday, September 10, at the Lake Street BIG10 Conference in New York. September 9, 2026 (Last night): HIGHLIGHT: Announcement of highly successful pilot stability data (forced degradation) confirming a molecular structure identical to BOTOX®. Backed by this sensational laboratory data, AEON Biopharma is demonstrating to the entire medical community that its blockbuster candidate, ABP-450, is in no way inferior to the multi-billion-dollar original, BOTOX®! Driven by a top-tier leadership team of former FDA executives and rock-solid financing, this biotech gem is catapulting itself today from a state of extreme undervaluation straight to the top of global watchlists. 💡 This news represents a fundamental milestone, as it virtually eliminates the company's greatest scientific risk—potential biological dissimilarity to the original BOTOX® product—using hard laboratory data.
0 · Reply